JPWO2022270524A1 - - Google Patents
Info
- Publication number
- JPWO2022270524A1 JPWO2022270524A1 JP2022542938A JP2022542938A JPWO2022270524A1 JP WO2022270524 A1 JPWO2022270524 A1 JP WO2022270524A1 JP 2022542938 A JP2022542938 A JP 2022542938A JP 2022542938 A JP2022542938 A JP 2022542938A JP WO2022270524 A1 JPWO2022270524 A1 JP WO2022270524A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103819 | 2021-06-23 | ||
| PCT/JP2022/024814 WO2022270524A1 (ja) | 2021-06-23 | 2022-06-22 | 癌の治療及び／又は予防のための医薬品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022270524A1 true JPWO2022270524A1 (https=) | 2022-12-29 |
| JPWO2022270524A5 JPWO2022270524A5 (https=) | 2025-06-06 |
Family
ID=84545446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542938A Pending JPWO2022270524A1 (https=) | 2021-06-23 | 2022-06-22 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250228937A1 (https=) |
| EP (1) | EP4360649A4 (https=) |
| JP (1) | JPWO2022270524A1 (https=) |
| KR (1) | KR20240024803A (https=) |
| CN (1) | CN117460532A (https=) |
| AU (1) | AU2022298240A1 (https=) |
| BR (1) | BR112023026992A2 (https=) |
| CA (1) | CA3225422A1 (https=) |
| MX (1) | MX2023014500A (https=) |
| WO (1) | WO2022270524A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230139178A1 (en) * | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
| WO2025206085A1 (ja) * | 2024-03-28 | 2025-10-02 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| US6677436B1 (en) | 1998-04-03 | 2004-01-13 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| DE10359795A1 (de) | 2003-12-19 | 2005-07-21 | Bayer Technology Services Gmbh | Strangverdampfervorrichtung |
| KR101638490B1 (ko) | 2008-08-05 | 2016-07-11 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
| AU2010270979B2 (en) | 2009-06-22 | 2015-04-23 | Medimmune, Llc | Engineered Fc regions for site-specific conjugation |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| HUE025678T2 (en) | 2010-02-04 | 2016-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| BR112012018943A8 (pt) | 2010-02-04 | 2017-12-19 | Toray Industries | medicamento e método para o tratamento e/ou prevenção de um câncer |
| RU2598258C2 (ru) | 2010-02-04 | 2016-09-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| MX340015B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| BR112012024489A2 (pt) | 2010-03-29 | 2016-05-31 | Zymeworks Inc | anticorpos com função efetora suprimida ou aumentada |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| PT2740794T (pt) | 2011-08-04 | 2018-06-14 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
| KR102041832B1 (ko) | 2011-08-04 | 2019-11-08 | 도레이 카부시키가이샤 | 췌장암의 치료 및/또는 예방용 의약 조성물 |
| JP6070191B2 (ja) | 2011-08-04 | 2017-02-01 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PT2818483T (pt) | 2012-02-21 | 2017-10-09 | Toray Industries | Composição medicinal para tratamento e/ou prevenção de cancro |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| HUE044611T2 (hu) | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| PT2832366T (pt) | 2012-03-30 | 2018-01-25 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar |
| KR102155531B1 (ko) | 2012-03-30 | 2020-09-15 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| ES2704909T3 (es) | 2013-08-09 | 2019-03-20 | Toray Industries | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| JP7342701B2 (ja) * | 2018-03-30 | 2023-09-12 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| US20230139178A1 (en) * | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3175127A1 (en) * | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
-
2022
- 2022-06-22 AU AU2022298240A patent/AU2022298240A1/en active Pending
- 2022-06-22 CN CN202280041252.1A patent/CN117460532A/zh active Pending
- 2022-06-22 JP JP2022542938A patent/JPWO2022270524A1/ja active Pending
- 2022-06-22 WO PCT/JP2022/024814 patent/WO2022270524A1/ja not_active Ceased
- 2022-06-22 BR BR112023026992A patent/BR112023026992A2/pt unknown
- 2022-06-22 US US18/573,641 patent/US20250228937A1/en active Pending
- 2022-06-22 CA CA3225422A patent/CA3225422A1/en active Pending
- 2022-06-22 MX MX2023014500A patent/MX2023014500A/es unknown
- 2022-06-22 EP EP22828440.2A patent/EP4360649A4/en active Pending
- 2022-06-22 KR KR1020237042093A patent/KR20240024803A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022298240A1 (en) | 2024-01-18 |
| EP4360649A1 (en) | 2024-05-01 |
| EP4360649A4 (en) | 2025-06-25 |
| US20250228937A1 (en) | 2025-07-17 |
| BR112023026992A2 (pt) | 2024-03-12 |
| KR20240024803A (ko) | 2024-02-26 |
| CA3225422A1 (en) | 2022-12-29 |
| CN117460532A (zh) | 2024-01-26 |
| MX2023014500A (es) | 2024-01-25 |
| WO2022270524A1 (ja) | 2022-12-29 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20230803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250529 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250529 |